MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...
MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...
Riyadh, November 19, 2023, SPA -- An agreement was signed today at the Ministry of Industry and Mineral Resources between Dammam Pharma, 85% owned by Spimaco, and MSD to manufacture type 2 diabetes ...
Our Website is outdated and broken, please DO NOT use it (https://modernizr.com) but rather build your modernizr version from npm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback